SZSE Ticker: 300702

Zhejiang Tianyu Pharmaceutical Co., Ltd.

浙江天宇药业股份有限公司

天宇股份

TIANYU PHARMA

Listing Date: 2017-09-19

Board: GEM

Industry Classification: Manufacturing

Yongying Medical and Health's stock C net value rose 3.82%_Sina Finance_Sina.com

Yongying Medical and Health's stock C net value rose 3.82%_Sina Finance_Sina.com

Yongying Medical and Health stock A net value rose 3.83% stock_Sina Finance_Sina.com

Societe Generale Healthcare Mixed A Net Worth Up 3.11% Societe Generale

Societe Generale Healthcare Hybrid C Net Worth Up 3.10% Societe Generale

Zheshang Pharmaceutical API Summary: Supply Chain ROE Improves Manufacturing End Product Upgrade

Exposure of hidden stocks of funds

Are Top-Row Funds optimistic about the A-share market outlook? The latest collection of the fund's hidden heavy holding stocks reveals the secrets, Ge Lan increases his holdings of "Yao Mao", and Xie Zhiyu aggressively buys new energy Stock Financial Industry

Are top-tier funds optimistic about the market outlook for A-shares? The latest collection of the fund's hidden heavy holding stocks reveals the secret of Ge Lan's increase in holdings of "Yao Mao" Xie Zhiyu aggressively buys new energy

Zheshang Securities gives Tianyu an overweight rating: quarter-on-quarter improvement, a new starting point in 2022

Zheshang Securities gives Tianyu an overweight rating: quarter-to-quarter improvement, a new starting point in 2022 – yqqlm

[Graphic Quarterly Report] Comments on the 2022 First Quarterly Report of Yongying Medical and Health A Fund_Oriental Fortune Network

Zhongtai Securities: Give Tianyu a Buy rating_Stock News_Market Gold Online

Zhongtai Securities gave Tianyu a buy rating: the performance is expected to turn upward, and the new varieties of CDMO and API are expected to grow rapidly.

Zhongtai Securities gave Tianyu a buy rating: the performance is expected to turn upward, and the new varieties of CDMO and API are expected to grow rapidly – yqqlm

Tianyu Co., Ltd. announced the 2021 annual equity distribution plan to distribute 1 yuan per 10

IPO observation Haisen Pharmaceutical's heavy single product supervision risk is high and low R&D investment may be difficult to support the road of transformation

IPO observation Haisen Pharmaceutical's heavy single product supervision risk is high and low R&D investment may be difficult to support the road of transformation.

Yongying Medical and Health stock A net value fell 4.06% stock_Sina Finance_Sina.com

Yongying Medical and Health's stock C net value fell 4.05%_Sina Finance_Sina.com

Societe Generale Healthcare Hybrid C Net Worth Down 3.10% Societe Generale

Want to see more data? Registered subscribers can see all the data.